What is it about?
Tumor-infiltrating lymphocytes (TILs) play key roles in antitumor immune responses. This study explores the impact of somatic mutations in TILs on antitumor immunity. Through whole-genome sequencing, we identified several somatic mutations in TILs, including an SH2D2A frameshift mutation and a TNFAIP3 deletion. These somatic mutations activated T cell effector functions and antitumor immunity both in vitro and in vivo.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
This study provides direct evidence that somatic mutations in TILs increase antitumor immunity, leading to novel biomarkers and therapeutic targets. We highlight the significance of “somatic mutations in TILs” in antitumor immunity.
Read the Original
This page is a summary of: Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity, Proceedings of the National Academy of Sciences, August 2024, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2320189121.
You can read the full text:
Contributors
The following have contributed to this page